vs
Axogen, Inc.（AXGN）与TransMedics Group, Inc.（TMDX）财务数据对比。点击上方公司名可切换其他公司
TransMedics Group, Inc.的季度营收约是Axogen, Inc.的2.7倍（$160.8M vs $59.9M）。TransMedics Group, Inc.净利率更高（65.6% vs -22.0%，领先87.5%）。TransMedics Group, Inc.同比增速更快（32.2% vs 21.3%）。TransMedics Group, Inc.自由现金流更多（$19.0M vs $1.8M）。过去两年TransMedics Group, Inc.的营收复合增速更高（28.8% vs 20.3%）
Axogen总部位于美国佛罗里达州阿拉楚阿，是外科解决方案提供商，专注开发周围神经损伤修复相关产品，涵盖人体组织移植物、神经连接器、软组织膜等，旗下AVANCE细胞移植技术可模拟人体神经结构，临床数据显示其产品帮助87%的周围神经损伤患者实现感觉与运动功能恢复，2013年完成1800万美元首次公开募股。
TransMedics Group, Inc.是一家专注于器官移植领域的医疗科技企业，核心产品器官护理系统可在运输过程中维持捐献器官的活性，提升心、肺、肝、肾移植手术的成功率，服务覆盖北美、欧洲及亚太地区的移植中心与器官获取组织。
AXGN vs TMDX — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $59.9M | $160.8M |
| 净利润 | $-13.2M | $105.4M |
| 毛利率 | 74.1% | 58.1% |
| 营业利润率 | -16.3% | 13.2% |
| 净利率 | -22.0% | 65.6% |
| 营收同比 | 21.3% | 32.2% |
| 净利润同比 | -3023.6% | 1436.9% |
| 每股收益（稀释后） | $-0.28 | $2.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $59.9M | $160.8M | ||
| Q3 25 | $60.1M | $143.8M | ||
| Q2 25 | $56.7M | $157.4M | ||
| Q1 25 | $48.6M | $143.5M | ||
| Q4 24 | $49.4M | $121.6M | ||
| Q3 24 | $48.6M | $108.8M | ||
| Q2 24 | $47.9M | $114.3M | ||
| Q1 24 | $41.4M | $96.8M |
| Q4 25 | $-13.2M | $105.4M | ||
| Q3 25 | $708.0K | $24.3M | ||
| Q2 25 | $579.0K | $34.9M | ||
| Q1 25 | $-3.8M | $25.7M | ||
| Q4 24 | $450.0K | $6.9M | ||
| Q3 24 | $-1.9M | $4.2M | ||
| Q2 24 | $-1.9M | $12.2M | ||
| Q1 24 | $-6.6M | $12.2M |
| Q4 25 | 74.1% | 58.1% | ||
| Q3 25 | 76.6% | 58.8% | ||
| Q2 25 | 74.2% | 61.4% | ||
| Q1 25 | 71.9% | 61.5% | ||
| Q4 24 | 76.1% | 59.2% | ||
| Q3 24 | 74.9% | 55.9% | ||
| Q2 24 | 73.8% | 60.6% | ||
| Q1 24 | 78.8% | 61.9% |
| Q4 25 | -16.3% | 13.2% | ||
| Q3 25 | 3.2% | 16.2% | ||
| Q2 25 | 3.0% | 23.2% | ||
| Q1 25 | -3.4% | 19.1% | ||
| Q4 24 | 4.1% | 7.1% | ||
| Q3 24 | -0.6% | 3.6% | ||
| Q2 24 | -0.9% | 10.9% | ||
| Q1 24 | -11.0% | 12.8% |
| Q4 25 | -22.0% | 65.6% | ||
| Q3 25 | 1.2% | 16.9% | ||
| Q2 25 | 1.0% | 22.2% | ||
| Q1 25 | -7.9% | 17.9% | ||
| Q4 24 | 0.9% | 5.6% | ||
| Q3 24 | -3.8% | 3.9% | ||
| Q2 24 | -4.0% | 10.7% | ||
| Q1 24 | -16.0% | 12.6% |
| Q4 25 | $-0.28 | $2.59 | ||
| Q3 25 | $0.01 | $0.66 | ||
| Q2 25 | $0.01 | $0.92 | ||
| Q1 25 | $-0.08 | $0.70 | ||
| Q4 24 | $-0.00 | $0.19 | ||
| Q3 24 | $-0.04 | $0.12 | ||
| Q2 24 | $-0.04 | $0.35 | ||
| Q1 24 | $-0.15 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.5M | — |
| 总债务越低越好 | $48.4M | — |
| 股东权益账面价值 | $128.8M | $473.1M |
| 总资产 | $221.7M | $1.1B |
| 负债/权益比越低杠杆越低 | 0.38× | — |
8季度趋势，按日历期对齐
| Q4 25 | $41.5M | — | ||
| Q3 25 | $35.8M | — | ||
| Q2 25 | $29.9M | — | ||
| Q1 25 | $22.1M | — | ||
| Q4 24 | $33.5M | — | ||
| Q3 24 | $24.5M | $330.1M | ||
| Q2 24 | $21.1M | $362.8M | ||
| Q1 24 | $17.6M | $350.2M |
| Q4 25 | $48.4M | — | ||
| Q3 25 | $48.2M | — | ||
| Q2 25 | $47.9M | — | ||
| Q1 25 | $47.7M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $47.3M | — | ||
| Q2 24 | $47.0M | — | ||
| Q1 24 | $46.8M | — |
| Q4 25 | $128.8M | $473.1M | ||
| Q3 25 | $120.8M | $355.2M | ||
| Q2 25 | $112.3M | $318.1M | ||
| Q1 25 | $105.4M | $266.3M | ||
| Q4 24 | $103.9M | $228.6M | ||
| Q3 24 | $99.4M | $209.9M | ||
| Q2 24 | $95.7M | $189.9M | ||
| Q1 24 | $93.2M | $159.5M |
| Q4 25 | $221.7M | $1.1B | ||
| Q3 25 | $216.4M | $946.0M | ||
| Q2 25 | $205.5M | $890.5M | ||
| Q1 25 | $196.2M | $837.5M | ||
| Q4 24 | $203.7M | $804.1M | ||
| Q3 24 | $192.0M | $785.6M | ||
| Q2 24 | $188.9M | $758.6M | ||
| Q1 24 | $186.5M | $723.8M |
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | 0.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $34.5M |
| 自由现金流经营现金流 - 资本支出 | $1.8M | $19.0M |
| 自由现金流率自由现金流/营收 | 3.0% | 11.8% |
| 资本支出强度资本支出/营收 | 2.1% | 9.7% |
| 现金转化率经营现金流/净利润 | — | 0.33× |
| 过去12个月自由现金流最近4个季度 | $-2.9M | $133.6M |
8季度趋势，按日历期对齐
| Q4 25 | $3.0M | $34.5M | ||
| Q3 25 | $3.2M | $69.6M | ||
| Q2 25 | $7.7M | $91.6M | ||
| Q1 25 | $-13.2M | $-2.9M | ||
| Q4 24 | $8.7M | $19.7M | ||
| Q3 24 | $3.9M | $6.9M | ||
| Q2 24 | $4.2M | $25.7M | ||
| Q1 24 | $-12.3M | $-3.4M |
| Q4 25 | $1.8M | $19.0M | ||
| Q3 25 | $1.7M | $61.9M | ||
| Q2 25 | $7.0M | $82.5M | ||
| Q1 25 | $-13.4M | $-29.9M | ||
| Q4 24 | $8.1M | $6.1M | ||
| Q3 24 | $3.3M | $-41.3M | ||
| Q2 24 | $3.3M | $2.0M | ||
| Q1 24 | $-13.2M | $-47.6M |
| Q4 25 | 3.0% | 11.8% | ||
| Q3 25 | 2.8% | 43.1% | ||
| Q2 25 | 12.4% | 52.4% | ||
| Q1 25 | -27.7% | -20.8% | ||
| Q4 24 | 16.3% | 5.0% | ||
| Q3 24 | 6.8% | -38.0% | ||
| Q2 24 | 6.8% | 1.7% | ||
| Q1 24 | -31.9% | -49.2% |
| Q4 25 | 2.1% | 9.7% | ||
| Q3 25 | 2.5% | 5.3% | ||
| Q2 25 | 1.3% | 5.8% | ||
| Q1 25 | 0.5% | 18.8% | ||
| Q4 24 | 1.4% | 11.2% | ||
| Q3 24 | 1.2% | 44.3% | ||
| Q2 24 | 1.9% | 20.8% | ||
| Q1 24 | 2.2% | 45.6% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | 4.55× | 2.86× | ||
| Q2 25 | 13.35× | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | 19.41× | 2.87× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXGN
暂无分部数据
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
